Date Closed

January 3, 2008

Lead Office

Toronto

Value

943.00 Million USD

On January 3, 2008 Galenica AG completed its acquisition of Aspreva Pharmaceuticals Corporation pursuant to a statutory plan of arrangement under which Aspreva shareholders received US$26.00  per share in cash. The aggregate consideration paid pursuant to the plan of arrangement was approximately US$943 million and was financed by term and revolving credit facilities of US$950 million and CHF$150 million provided by The Royal Bank of Scotland plc.

McCarthy Tétrault advised Asperva with a team that included Gary Girvan, Lorna Telfer, Richard Balfour, Joseph Garcia, Orysia Semotiuk, Brian Vick, Salima Datoo, David Frost and Genevieve Pinto (securities/corporate), Madeleine Renaud (competition), Patrick McCay and Marc Darmo (tax) and John Pearson (life sciences).